Abstract
Natural killer (NK) cells, a major cell type of the innate immunity, express surface receptors that regulate potent effector functions such as cytolytic activity and release of cytokines playing a central role in inflammatory response and immunoregulation. In this contribution, we briefly outline the major steps from the discovery of human leukocyte antigen (HLA)-class I-specific inhibitory receptors in humans to recent successful clinical applications in the cure of high-risk leukemias both in adults and in pediatric patients. A central role is played by 'alloreactive' NK cells originated from donor's CD 34+ cells in eradicating leukemic cells in the setting of T-cell-depleted haploidentical hemopoietic stem cell transplantation. Because alloreactive NK cells play a central role also in preventing graft rejection and graft- vs-host disease, they may represent an ideal tool to treat patients affected by acute high-risk leukemias.
Original language | English |
---|---|
Pages (from-to) | 103-109 |
Number of pages | 7 |
Journal | Tissue Antigens |
Volume | 75 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2010 |
Keywords
- Activating receptors
- Acute lymphoblastic leukemias
- Acute myeloid leukemias
- Hemopoietic stem cell transplantation
- Killer immunoglobulin-like receptors
- Killer immunoglobulin-like repertoire
- Natural killer cells
ASJC Scopus subject areas
- Genetics
- Immunology
- Immunology and Allergy